Med Ed Report briefs

Seventy of 156 NIH grantee institutions responding to an OIG investigation have written policies addressing financial interests, and 69 have policies on institutional conflicts. Because NIH lacks insight into the number of financial conflicts of interest among these institutions, the OIG recommended that NIH issue regulations addressing same.

Pri-Med partnered with the American Society for Nutrition on a series of CME sessions designed to help raise PCPs' knowledge and understanding of nutrition-related topics. The series is due to launch at pmiCME Updates Day this month at Pri-Med Conference & Exhibition.

Haymarket Medical Education hired Kenny Cox as VP of educational development, responsible for securing pharma grants. Cox has held a number of executive positions at Primary Care Network.

A February article in Archives of Internal Medicine suggested that ACCME SCS are a “floor not a ceiling” and that more CME providers should stop accepting industry support, or limit it to a small percentage of income, stop using faculty who are also paid speakers or offering courses supported by a single grantor, and use pooled grants.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.